Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies

Stock Information for Citius Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Citius Pharmaceuticals Inc.

Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization
Citius Oncology Ships First International Order of LYMPHIR(TM) to Europe
Citius Oncology Provides Commercial Update on LYMPHIR(TM) Launch Highlighting Early Adoption and Expanding Clinical Development
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR(TM) in Discussions with Leading Cutaneous Lymphoma Experts
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR(TM) (E7777) Dosing Prior to Commercial CAR?T Therapy in High?Risk Diffuse Large B?Cell Lymphoma

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.